BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
4.490
-0.370 (-7.61%)
At close: Jan 15, 2026, 4:00 PM EST
4.330
-0.160 (-3.56%)
Pre-market: Jan 16, 2026, 5:57 AM EST
BriaCell Therapeutics Employees
BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change
10
Growth
166.67%
Revenue / Employee
n/a
Profits / Employee
-$1,794,204
Market Cap
8.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jul 31, 2023 | 16 | 10 | 166.67% |
| Jul 31, 2021 | 6 | 0 | - |
| Aug 1, 2019 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCTX News
- 13 hours ago - BriaCell Therapeutics Announces Closing of US$30 million Public Offering - GlobeNewsWire
- 2 days ago - BriaCell Therapeutics Announces Pricing of $30 million Public Offering - GlobeNewsWire
- 2 days ago - BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient - GlobeNewsWire
- 4 weeks ago - “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine - GlobeNewsWire
- 5 weeks ago - BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 - GlobeNewsWire
- 5 weeks ago - BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - GlobeNewsWire
- 6 weeks ago - BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025 - GlobeNewsWire
- 7 weeks ago - BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025 - GlobeNewsWire